Fuji Pharma Co., Ltd. | Investor Relations

Fuji Pharma Co., Ltd. TOP > Investor Relations

Corporate Profile

Top Message

Medium-term Business Plan

Consolidated Financial Highlights

IR Library

Stock Information

2020.5.20 Mid-term Business Plan FY9/2020 – FY9/2024
2020.5.20 Business Results of 2Q/FY2020
2020.5.8 Financial Results of 2Q/FY2020
2020.2.28 Development status of estetrol/drospirenone in Europe
2020.2.6 Financial Results of 1Q/FY2020
2019.11.19 Business Results of FY2019
2019.11.8 Financial Results of FY2019
2019.10.23 Manufacturing and marketing approval succession for l'estrogel 0.06% treatment for menopausal disorders
2019.10.18 Exhibition at CPhI Worldewide 2019
2019.10.4 Notice of Change of Representative Director (Change of President)
2019.8.29 Corporate Report 2019(English version) has been published
2019.8.8 Financial Results of 3Q/FY2019